Pharmaceuticals
Clarivate Announces Gordon Samson as President, Intellectual Property and Nominates Dr. Saurabh Saha as New Independent Director
Naming the first of three business leaders for its newly created market segments and nominating new Independent Director to its Board LONDON, March 24, 2023 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a global leader in connecting people and organizations to intelligence they can trust, today an...
2023-03-24 04:30
4098
Northumbria Healthcare NHSFT and C-POLAR Technologies combine innovation in widely acclaimed hub
This partnership will create infection-resilient environments as C-POLAR
captures, inactivates, and eradicates up to 99.99% of viruses, bacteria, and
fungi
HONG KONG, March 23, 2023 /PRNewswire/ -- C-POLAR Technologies, Inc.
2023-03-23 20:32
2777
Everest Medicines Announces Signing of an MOU for Strategic Cooperation with Guangdong Academy of Medical Sciences in Renal Diseases
GUANGZHOU, China, March 23, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced today that it has signed an MOU for comprehen...
2023-03-23 17:52
3941
Transcenta Announces First Patient Dosed in the U.S. Study of Its First-In-Class Gremlin1 Targeting Antibody TST003 for the Treatment of Solid Tumors
SUZHOU, China, March 23, 2023 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics,announces the successful dos...
2023-03-23 08:00
3236
Daewoong Pharmaceutical's Envlo to enter the global market in full swing with filing for product license in three ASEAN countries
* Submitted an NDA to Indonesia, Philippines and Thailand * Signed the export contract in Brazil and Mexico in last February * Aiming to enter 50 countries by 2030 SEOUL, South Korea, March 22, 2023 /PRNewswire/ -- Daewoong Pharmaceutical began the advance into the global market in full swin...
2023-03-22 21:20
4790
3SBio announces 2022 annual results, with revenue rising 7.5% year on year and normalized net profit attributable to parents jumping 25.2%
HONG KONG, March 22, 2023 /PRNewswire/ -- Chinese leading biopharmaceutical company 3SBio (01530.HK) today announced its 2022 annual results. In 2022, 3SBio's core biopharmaceutical products posted robust growth, hair health business achieved blistering performance, and contract development and ...
2023-03-22 11:15
5599
DEBIOPHARM ANNOUNCES LAUNCH OF THE PHASE 1/2 GaLuCi™ STUDY FOR ITS CA IX-TARGETED RADIOPHARMACEUTICAL PROGRAM
* Debiopharm is developing personalized radiotherapy through a theranostic approach, combiningdiagnostic imaging (Debio 0328 a gallium-labelled imaging tool) and therapeutic components (Debio 0228, a lutetium-labelled radioligand), thus allowing the pre-identification and treatment of patients ...
2023-03-22 09:00
2540
Two-Component Recombinant COVID-19 Vaccine ReCOV Granted With Emergency Use Authorization In Mongolia
TAIZHOU, China, March 21, 2023 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group") is pleased to announce that in accordance with the Mongolian law on the prevention of novel coronavirus (SARS-CoV-2) outbreak, the Company was granted an...
2023-03-21 13:59
4601
BLA Accepted in China for Boan Biotech's Denosumab Injection (BA1102) for the Oncology Indications
YANTAI, China, March 21, 2023 /PRNewswire/ -- Luye Pharma Group today announced that the Biologics License Application (BLA) for BA1102 (Denosumab Injection), a biosimilar for the oncology indications developed by its subsidiary Boan Biotech, has been accepted inChina by the Center for Drug Evalu...
2023-03-21 13:46
4608
Innovent Announces Clinical Data of Multiple Trials Will be Presented at the AACR Annual Meeting 2023
ROCKVILLE, Md. and SUZHOU, China, March 21, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology ...
2023-03-21 08:00
5171
Sirnaomics to Present Latest Developments in Polypeptide Nanoparticle Platform at the 4th Annual RNAi-Based Therapeutics Summit
HONG KONG and GERMANTOWN, Md. and SUZHOU BIOBAY, China, March 20, 2023 /PRNewswire/ -- Sirnaomics Ltd. (the "Company", Stock Code: 2257.HK, and together with its subsidiaries, the"Group" or "Sirnaomics"), a leading biopharmaceutical company in the discovery and development of advanced RNAi thera...
2023-03-20 23:27
3817
Transcenta Holding Limited (6628.HK) to Hold 2022 Annual Results Release Conference Call
SUZHOU, China, March 20, 2023 /PRNewswire/ -- The management team of Transcenta Holding Limited (06628.HK) will attend the 2022 annual results release conference call onMarch 31, 2023. Transcenta is a clinical stage biopharmaceutical company with fully integrated capabilities in the discovery, r...
2023-03-20 21:12
2759
Guo Guangchang Stresses Healthy Corporate Development and Expresses Full Confidence in the Future
HONG KONG, March 20, 2023 /PRNewswire/ -- On 17 and 18 March, Guo Guangchang, Chairman of Fosun International, attended the 23rd Annual Conference of Yabuli China Entrepreneurs Forum 2023, and the 6th Shanghai Forum Themed Zhejiang Entrepreneurs in the World & the 11th Member Representative Confe...
2023-03-20 17:12
3448
ETANA HAS SECURED FINANCING FROM DEG, EAST VENTURES AND OTHER GLOBAL INVESTORS
JAKARTA, Indonesia, March 20, 2023 /PRNewswire/ -- PT Etana Biotechnologies Indonesia (Etana), an Indonesian biopharmaceutical company, has secured a new round of investment led by DEG followed by Yunfeng Capital, HighLight Capital and East Ventures. This round of financing will be used for fu...
2023-03-20 15:22
4429
Antengene Announces Five Upcoming Presentations at the 2023 American Association for Cancer Research Annual Meeting
– Five posters will showcase progress with multiple preclinical and clinical programs, including the clinical results ofATG-008 (mTORC1/2 inhibitor) and preclinical data ofATG-031 (anti-CD24 monoclonal antibody), ATG-037 (small molecule CD73 inhibitor), ATG-017 (ERK1/2 inhibitor), and ATG-034 (L...
2023-03-20 15:20
2825
China's first personalized neoantigen-targeted cancer vaccine receives NMPA's clinical trial approval
BEIJING, March 17, 2023 /PRNewswire/ -- According the latest data released at the Clinical Trials Implied Approval section on the website ofChina's Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA), Likang Life Sciences (hereinafter referred to as "Likang") h...
2023-03-17 14:56
2687
YS BIOPHARMA TO RING THE OPENING BELL AND DEBUT ON NASDAQ
YS Biopharma Ordinary Shares and Warrants to Trade on the Nasdaq Under Tickers "YS" and "YSBPW" NEW YORK, March 17, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (the "Company" or "YS Biopharma"), a global biopharmaceutical company focusing on new generations of vaccines and therapeutic biologic...
2023-03-17 04:30
3134
Bolstering Healthcare Quality in Malaysia with Renowned Flagship Hospitals
Malaysia's position as a safe and trusted destination for high-quality healthcare services is reinforced with the debut of flagship medical tourism hospitals in the country. KUALA LUMPUR, Malaysia, March 16, 2023 /PRNewswire/ -- Malaysia has debuted its first-of-its-kind Flagship Medical Tourism...
2023-03-16 16:12
6140
The FDA has approved the CSF-1R inhibitor Pimicotinib (ABSK021) of Abbisko Therapeutics to enter the Pivotal Global Multi-center Phase III Clinical Trial
This is the first-ever global phase III trial for TGCT approved by NMPA and FDA. Pimicotinib（ABSK021）was granted BTD by FDA and CDE, discovered and developed byChina biotech。 SHANGHAI, March 16, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. (HKEX Stock Code: 2256. HK, referred to as "Abbis...
2023-03-16 10:00
5782
Alphamab Oncology Announces the First Patient Dosed in the Phase I Trial of Anti-HER2 bispecific ADC JSKN003
SUZHOU, China, March 16, 2023 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been dosed with 2.1mg/kg in a Phase I clinical study (JSKN003-102) of JSKN003, an Anti-HER2 bispecific ADC. ADC drugs have the advantages of highly specific targeting of anti...
2023-03-16 09:58
3435
Week's Top Stories
Most Reposted
Agoda Releases AI Developer Report 2026: Agentic AI Adoption Outpaces Enterprise Readiness Across Southeast Asia and India
[Picked up by 294 media titles]
2026-09-24 10:30
Malaysia Calls for Shift from Halal-Certified to Halal-Competitive as ASEAN Targets USD5 Trillion Global Halal Economy
[Picked up by 277 media titles]
2026-09-25 14:45
HLB's Flagship CIO Fund Launched with Strategic Alliance with Lombard Odier
[Picked up by 276 media titles]
2026-09-28 23:04
Responsible Fintech Institute Appoints Four Executive Fellows and Elevates Distinguished Professor Patrick H. M. Loh to Co-Founder
[Picked up by 276 media titles]
2026-09-29 09:00
DOKU Names Himelda Renuat CEO as Ant International's Antom Deepens Strategic Investment in Indonesia's Payments Leader
[Picked up by 274 media titles]
2026-09-24 10:00
Most Read
Brightray Signs Prefabricated Module Sales Framework Agreement for Planned 40MW AI Data Center Project in Macao
2026-09-25 20:30
13849
Envision Energy Secures TÜV SÜD Certificate for Wind Farm Control System, Strengthening Long-Term Resilience for Future Energy Systems
2026-09-25 20:11
12561
ULTRALOQ Launches Next-Generation Smart Lock Collection: Refining Home Entry with Natural, Intelligent and Trusted Access Solutions
2026-09-26 02:46
11591
